- Conditions
- NLRC4-MAS, XIAP Deficiency
- Interventions
- Tadekinig alfa, 0.9% sodium chloride
- Drug · Other
- Lead sponsor
- AB2 Bio Ltd.
- Industry
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 6
- States / cities
- La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–38
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Gallium 68 Macro-aggregated albumin
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 40 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- NOMID, DIRA, NLRC4-MAS, SAVI, CANDLE
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 99 Years
- Enrollment
- 3,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Fibrous Dysplasia
- Interventions
- denosumab
- Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 4 Years to 14 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease
- Interventions
- Emapalumab
- Drug
- Lead sponsor
- Swedish Orphan Biovitrum
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Fibrous Dysplasia/McCune-Albright Syndrome
- Interventions
- MRI-based Neuroimaging, Non-contrast MRI, 18F-FDG-PET/CT, 18F-NaF-PET/CT
- Diagnostic Test
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 10 Years to 45 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Anemia, Aplastic, Red-Cell Aplasia, Pure, Anemia, Diamond-Blackfan
- Interventions
- Rituximab
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Polyostotic Fibrous Dysplasia
- Interventions
- Fosamax (Alendronate)
- Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 6 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Interventions
- Angiotensin 1-7, Saline solution
- Drug
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Tucson, Arizona
- Conditions
- Fibrous Dysplasia, McCune Albright Syndrome, Mazabraud Syndrome
- Interventions
- Not listed
- Lead sponsor
- Tovah Burstein
- Other
- Eligibility
- Not listed
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations
- Interventions
- MAS825, Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 0 Years to 100 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 4
- States / cities
- Cincinnati, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more
- Conditions
- Polyostotic Fibrous Dysplasia
- Interventions
- Not listed
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 4 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Meconium Aspiration
- Interventions
- Lucinactant, Standard Care
- Drug · Other
- Lead sponsor
- Windtree Therapeutics
- Industry
- Eligibility
- Up to 48 Hours
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Warrington, Pennsylvania
- Conditions
- Polyostotic Fibrous Dysplasia, Precocious Puberty
- Interventions
- Testolactone
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1982 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland